The Columbus Dispatch, October 8, 2012

OhioHealth recently spent $3.5 million on equipment for a less-invasive treatment of benign but sometimes problematic tumors that grow on the uterus. And the health system has spent additional money to advertise the outpatient uterine-fibroid procedure, which was approved by the U.S. Food and Drug Administration eight years ago. OhioHealth officials said they anticipated some initial push-back from insurers to paying for the procedure, which OhioHealth had expected to perform 80 to 100 times a year by 2014. But the reluctance, they said, has been far greater than expected from health insurers such as Anthem, Aetna and Medical Mutual of Ohio.

Facebook icon
LinkedIn icon
Twitter icon